The drug is indicated for the treatment of seasonal allergies such as itchy nose and sneezing.
The launching of the drug follows the US Food and Drug Administration (FDA) approval for the abbreviated new drug application (ANDA) for Fexofenadine HCl and Pseudoephedrine HCl extended release tablets in June this year.
Fexofenadine HCl and Pseudoephedrine HCl extended release tablets are the generic version of Allegra D24 Hour extended release tablets of Sanofi-aventis.